ArticleBMC infectious diseases2025
Effect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: a community-based cohort study (K-SEROSMART Wave 2).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protective Effectiveness of Sars-Cov-2 Infection Risk Among Hybrid, Vaccine, and Infection-induced Immunity Against the Omicron Variant, K-Serosmart.Open forum infectious diseases · 2026Article
- The impact of human behavioral adaptation stratified by immune status on COVID-19 spread with application to South Korea.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19) continues to impact populations globally, raising concerns about immunity levels and risks to high-risk groups despite the lifting of the global health emergency in May 2023. While studies have tracked seroprevalence, few have comprehensively assessed long-term antibody persistence and COVID-19 risk, particularly regarding immunity changes due to vaccination and infection. This study aimed to estimate the population prevalence of SARS-CoV-2-specific antibodies, including anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies, and to assess the risk of newly confirmed COVID-19 infections in Korea in December 2022. We conducted a follow-up survey and blood testing of 9,945 participants in the Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) Wave 1.
methodsThe K-SEROSMART Wave 2 study employed a staged approach through public health centers nationwide, using mobile web, telephone, and face-to-face surveys. The follow-up survey (Wave 2) was conducted between December 6 and 27, 2022, four months after the initial survey (Wave 1) conducted in August 2022. Participants self-reported sociodemographic characteristics and health status and provided blood samples for the analysis of anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies via electrochemiluminescence immunoassay. Population prevalence estimates were weighted for demographic data. Multivariate Cox proportional hazards regression was used to assess the relationship between anti-S antibody titers from Wave 1 and new COVID-19 cases, adjusting for age and sex.
resultsA total of 7,528 individuals participated, yielding a follow-up rate of 74.9%. The population-adjusted prevalence rates of anti-S and anti-N antibodies were 98.5% and 70.0%, respectively. The percentage of newly confirmed COVID-19 cases was significantly higher in individuals with anti-S antibody titers below 2,000 U/mL, 2,000-3,999 U/mL, 4,000-5,999 U/mL, 6,000-7,999 U/mL, and 8,000-9,999 U/mL than in those with titers above 18,000 U/mL (hazard ratio [HR] = 9.9, 95% confidence interval [CI] = 7.2-13.5; HR = 8.1, 95% CI = 5.8-11.3; HR = 7.1, 95% CI = 5.0-10.1; HR = 4.2, 95% CI = 2.8-6.3; HR = 2.0, 95% CI = 1.2-3.3, respectively).
conclusionsThis study demonstrated the feasibility of conducting a seroepidemiological cohort survey on COVID-19 using a nationally representative sample. Additionally, this study quantified anti-S antibody titer levels that are associated with reduced risk of new infections within a community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.